Government scientists will begin human trials next week on a possible Ebola vaccine, after taking “extraordinary measures” to develop the drug quickly.
The vaccine has performed “extremely well” in animal tests, said Anthony Fauci, the director of the National Institutes of Health’s infectious diseases unit. It’s designed to inoculate patients from two strains of Ebola, including the one responsible for the outbreak in West Africa that has killed more than 1,500 people.
Despite the measures taken to speed up the development process, Fauci said it’s “impossible to predict” when a vaccine might be ready and approved for use by health care workers headed to West Africa.
The initial round of human trials will focus on the drug’s safety. Ultimately, 20 patients will receive the drug at NIH’s facilities in Maryland, where scientists will determine whether the drug is safe and whether it provokes the same “immune response” in humans that it does in chimpanzees. Test subjects won’t be given Ebola, and they cannot become infected with the virus by taking the vaccine, Fauci said.
He said NIH will have the results from this study by the end of the year. The next steps will depend on those results as well as the state of the Ebola outbreak.
Initial human tests are also set to begin soon for at least three other potential vaccines.
Developing a vaccine is different from developing a treatment for infected patients, Fauci stressed during a conference call with reporters. Experimental treatments have been provided to Ebola patients during the current outbreak even though they’ve never been tested in humans””because if you already have Ebola, you don’t have much to lose from taking a drug that might not work.
But because vaccines are administered to healthy people, there’s a higher bar to make sure they work, or at least aren’t dangerous. “The worst thing you could do,” Fauci said, is to release a vaccine that hasn’t been tested for safety and ends up making healthy people sick or more susceptible to Ebola.
“You really can’t predict what you might see,” he said.
NIH developed the drug in collaboration with GlaxoSmithKline. Getting a large drug company involved helps ensure that the vaccine can be produced in large quantities, Fauci said. Some experimental treatments were developed by smaller firms that have run out of their products.
- 1 High Court Vacancy Spells Trouble for Congress
- 2 The Winners and Losers From the South Carolina Republican Debate
- 3 Why Four Justices Were Against the Supreme Court’s Huge Gay-Marriage Decision
- 4 Democrats’ Vanishing Future
- 5 FBI’s Facial-Recognition Technology Has Achieved ‘Full Operational Capability’
What We're Following See More »
Much has been made of David Brooks’s recent New York Times column, in which confesses to missing already the civility and humanity of Barack Obama, compared to who might take his place. In NewYorker.com, Jeffrey Frank reminds us how critical such attributes are to foreign policy. “It’s hard to imagine Kennedy so casually referring to the leader of Russia as a gangster or a thug. For that matter, it’s hard to imagine any president comparing the Russian leader to Hitler [as] Hillary Clinton did at a private fund-raiser. … Kennedy, who always worried that miscalculation could lead to war, paid close attention to the language of diplomacy.”
“We haven’t seen a true leftist since FDR, so many millions are coming out of the woodwork to vote for Bernie Sanders; he is the Occupy movement now come to life in the political arena.” So says Bill Maher in his Hollywood Reporter cover story (more a stream-of-consciousness riff than an essay, actually). Conservative states may never vote for a socialist in the general election, but “this stuff has never been on the table, and these voters have never been activated.” Maher saves most of his bile for Donald Trump and Sarah Palin, writing that by nominating Palin as vice president “John McCain is the one who opened the Book of the Dead and let the monsters out.” And Trump is picking up where Palin left off.